Elsevier

Atherosclerosis

Volume 171, Issue 1, November 2003, Pages 145-155
Atherosclerosis

European guidelines on cardiovascular disease prevention in clinical practice

https://doi.org/10.1016/j.atherosclerosis.2003.10.001Get rights and content

References (0)

Cited by (103)

  • Application in nutrition: Cholesterol-lowering activity

    2021, Biologically Active Peptides: From Basic Science to Applications for Human Health
  • Protective effect of Fisetin against angiotensin II-induced apoptosis by activation of IGF-IR-PI3K-Akt signaling in H9c2 cells and spontaneous hypertension rats

    2019, Phytomedicine
    Citation Excerpt :

    Further, in vivo studies also demonstrated that SHR animals display significantly reduced levels of p-IGF1R, p-PI3K, p-AKT and SHR rats treated with fisetin significantly increased these cell survival proteins when compared to SHR-control (Fig. 5C and D). Cardiovascular disease is the leading cause of death globally and is a growing health concern (De Backer et al., 2003). Traditionally, research and therapy have focused to identify and inhibit the pathological hypertrophy, cardiac dysfunction and heart failure.

  • Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: Findings from the EUROASPIRE III survey

    2013, Atherosclerosis
    Citation Excerpt :

    The results of the EUROASPIRE III survey show that despite the clear evidence of the benefits of lipid-lowering treatment in secondary prevention, many coronary patients with dyslipidaemia are still inadequately treated and a significant number of patients on lipid-lowering therapy is still not reaching the treatment goals. Almost half of all coronary patients did not reach the LDL-C goal of ≤2.5 mmol/L and about the same percentage did not reach the total cholesterol goal of ≤4.5 mmol/L according to the Joint European Societies guidelines on cardiovascular disease prevention in everyday clinical practice published in 2003 [11]. It has to be stressed that there were considerable variations between the participating centres from 22 countries involved, in the distribution of serum lipids, the use of lipid-lowering drugs, and the proportion of coronary patients reaching the total cholesterol and LDL-C goals.

View all citing articles on Scopus
View full text